A new study at the University of Warwick, published today in the journal Angewandte Chemie International Edition, claims a revolution in cancer treatment could soon be underway following a breakthrough that may lead to a dramatic improvement in cancer survival rates.
1) ZL105 drug could potentially replace currently used anticancer drugs, study finds Posted:March 26, 2014
“Called ZL105, the drug is a compound based on the precious metal iridium. The study has found ZL105 could potentially replace currently used anticancer drugs, which become less effective over time, cause a wide-range of side-effects and damage healthy cells as well as cancerous. Commenting on the breakthrough, University of Warwick researcher and study co-author Dr Isolda Romero-Canelon said The energy-producing machinery in cancer cells works to the limit as it attempts to keep up with quick proliferation and invasion. This makes cancer cells susceptible to minor changes in the cell ‘power-house’. Our drug pushes cancer cells over the limit causing them to slow and shut down, whilst normal cells can cope with its effects”. Full Story: ZL105 drug could potentially replace currently used anticancer drugs!
Johns Hopkins Health Alert, Posted in Prostate Disorders on March 26, 2014 2) Promising Treatment for Metastatic Prostate Cancer
“Early results from an ongoing National Institutes of Health-funded clinical trial look promising for men who have metastatic prostate cancer — the kind that spreads to major organs such as the liver or lungs or to the bones or adrenal glands. The study, which was reported in a National Institutes of Health press release, is examining the effectiveness of combining chemotherapy with hormone therapy for advanced prostate cancer, and so far, the combination has extended three-year survival rates from 52.5 percent to 69 percent. Men with hormone-sensitive metastatic prostate cancer are typically treated first with androgen deprivation therapy (ADT), a hormone treatment that blocks or limits the production of male hormones, which results in reduced or slower-growing tumors. After researchers added the chemotherapy drug docetaxel at the start of the hormone therapy regimen, they noted significant improvement in survival among patients with the most advanced prostate cancer”.
The early study results were made public because both Food and Drug Administration (FDA)-approved drugs are available to be put to immediate use in patients with a high extent of metastatic prostate cancer. Researchers continue to study the combination therapy to determine its effectiveness in treating less extensive metastatic prostate cancer. Full Story: Promising Treatment for Metastatic Prostate Cancer
“We need to be reminded that life is here to enjoy but the opportunity to do so does not last forever”.
The New Denver Men’s Club
“Men Fighting Cancer To Win”